Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.
about
The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trialsThe pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraineMigraine: new molecular mechanisms.[How do sumatriptan and co. work? The action mechanisms of triptans].Possible role of alpha-adrenoceptor subtypes in acute migraine therapy.Safety profile of the triptans.A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasationCan we develop neurally acting drugs for the treatment of migraine?Migraine: new treatment options from molecular biology.New drugs for migraineOvarian hormones and migraine headache: understanding mechanisms and pathogenesis--part I.Experimental migraine models and their relevance in migraine therapy.New migraine and pain research.Current migraine management - patient acceptability and future approaches.The pharmacological management of migraine, part 1: overview and abortive therapy.Migraine: an overview.Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan.Animal models of headache: from bedside to bench and back to bedside.5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?Chemical mediators of migraine: preclinical and clinical observations.Serotonin and molecular neuroimaging in humans using PET.Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine.Emerging targets in migraine.Emerging drugs for migraine treatment.Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.Emerging treatments for the primary headache disorders.Lasmiditan for the treatment of migraine.Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.Pathophysiology of Migraine: A Disorder of Sensory Processing.Advances in drug development for acute migraine.Acute migraine therapy: new drugs and new approaches.Triptans and CGRP blockade - impact on the cranial vasculature.5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks.New targets for migraine therapy.The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients.Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential.Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
P2860
Q26829564-64303A30-4D95-4828-BDBC-92128A138C71Q27008834-593FF751-1E14-4932-9876-052E837685D2Q33220839-02846878-CAC9-44A5-8AFA-2E3888B080BBQ34647941-E173087C-B6F9-4602-9F29-D7AB74DF69ACQ35115423-D9E6FB67-B36F-4F9D-97E9-F778C580A6AFQ35194407-678070E8-A39F-4ACF-9ADE-7A47E673A327Q35693015-BBEEC478-B4DF-496E-9D81-2EA8B51A1CF9Q36240187-AA30763C-8F1C-439F-8482-942CCDB445F9Q36257220-262124F5-4B39-48F8-A690-6AD8989E8C39Q36332611-3F9CDE4B-77D6-48FA-A85E-CF3556B80631Q36367877-E4146E38-7633-4762-8153-F79983D6C8CDQ36474260-1500D9E5-DC5E-4591-9F38-9B3AA3ED7BD4Q36787453-E0683654-2828-4BA7-B833-FE452ACAC457Q37106936-F685D870-F54F-4D8A-AD80-E8319FEC1D7FQ37340160-2AF88553-9EC6-4CF1-B468-0E7129542602Q37627183-F388D007-D769-4068-B77D-F978A281FBF2Q37685635-F3684BCC-88CA-4338-BD7C-8796564AD1A8Q37699421-1EC4C338-0ECA-4017-85F5-CF6C6A9164FEQ37739587-277862CA-4E9C-41CC-8C04-77127AEECC6BQ37883455-D3F47B17-67CB-4758-9D2A-6C9EA31F345AQ37938794-BEFC3F41-EB11-4561-AFBE-D916634245D4Q38129436-3EA10F17-C2C6-45F9-8919-82B0A253E9E1Q38169593-72A2CCB2-B008-4B84-BAB6-F12BBCAD074FQ38303376-65606C5A-6056-4A50-A82A-F4F1991581F2Q38348229-712CF8E4-246A-442F-AC0E-30FA02974CA8Q38504746-CCEDDE0F-9267-4C90-9861-B3C8DCB0045AQ38771819-FDADED90-6269-46D4-A4F9-EB29106B56CAQ39012465-ECA19A2B-53EB-454F-B4F0-AFEA85B8EE10Q39127073-56C12A46-2773-41C1-82EF-8295AC749BF9Q39527265-13F2AE56-95E2-4645-8698-D6B0BF60F78DQ41642373-533ADE80-372A-4EBB-A566-72C33170AF29Q42706186-80079227-15D2-4874-A580-71F52B8E7319Q42882664-36AB7823-5117-4239-912E-2E71F8A068E4Q46279239-9E467A79-9DB5-41D7-9928-A27692A93769Q48021540-A23F30DA-F88E-4924-8E12-58D429F8EBCBQ48495487-84865971-1439-4135-87F6-CDFCDAE4B516Q52643768-A551DEC1-FBFA-48CD-8487-BDAAB0968B6EQ57481750-AC997F29-7516-463E-9EE2-A4656300EF48
P2860
Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Selective seratonin 1F (5-HT(1 ...... a randomised controlled trial.
@ast
Selective seratonin 1F (5-HT(1 ...... a randomised controlled trial.
@en
Selective seratonin 1F
@nl
type
label
Selective seratonin 1F (5-HT(1 ...... a randomised controlled trial.
@ast
Selective seratonin 1F (5-HT(1 ...... a randomised controlled trial.
@en
Selective seratonin 1F
@nl
prefLabel
Selective seratonin 1F (5-HT(1 ...... a randomised controlled trial.
@ast
Selective seratonin 1F (5-HT(1 ...... a randomised controlled trial.
@en
Selective seratonin 1F
@nl
P2093
P1433
P1476
Selective seratonin 1F (5-HT(1 ...... a randomised controlled trial.
@en
P2093
D J Goldstein
J M Schaus
K W Johnson
L A Phebus
N M Ramadan
P304
P356
10.1016/S0140-6736(01)06347-4
P407
P577
2001-10-01T00:00:00Z